Correspondence
Looking for predictive markers in breast cancer We read with interest the findings of the IMELDA trial.1 This open-label, multicentre, phase 3 study assessed progression-free survival in previously untreated patients with metastatic breast cancer after the addition of capecitabine to bevacizumab as maintenance treatment after three to six courses of docetaxel plus bevacizumab. Gligorov and colleagues noted a significant improvement in progression-free survival (median 11·9 months [95% CI 9·8–15·4] for patients treated with bevacizumab and capecitabine vs 4·3 months [3·9–6·8] for patients treated with bevacizumab alone; stratified hazard ratio [HR] 0·38 [95% CI 0·27–0·55]; two-sided log-rank p
Looking for predictive markers in breast cancer We read with interest the findings of the IMELDA trial.1 This open-label, multicentre, phase 3 study assessed progression-free survival in previously untreated patients with metastatic breast cancer after the addition of capecitabine to bevacizumab as maintenance treatment after three to six courses of docetaxel plus bevacizumab. Gligorov and colleagues noted a significant improvement in progression-free survival (median 11·9 months [95% CI 9·8–15·4] for patients treated with bevacizumab and capecitabine vs 4·3 months [3·9–6·8] for patients treated with bevacizumab alone; stratified hazard ratio [HR] 0·38 [95% CI 0·27–0·55]; two-sided log-rank p
